Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) Offers Product Summary


Dallas, Texas 02/25/2014 (FINANCIALSTRENDS) – Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) is a one of the high net worth pharmaceutical companies which has a market capital $343.20 million. On the markets, the stock trades have infra-day trading between $3.38 low and $3.58 high. The company 52-week high of $9.41 and low of $2.26, with the stock opening at $3.40 and Beta is 0.86. The shares for the company are 96.68 million with the EPS- 0.62.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) has since reported the portfolio development as well as the rights to indigenous technology, proprietary standards of their new compound. This new drug solution will allow the company to establish itself further in the chronic hepatits C or HCV sector. The company has also provided a summary of the milestones it expects to meet by the end of year.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) is in a New Haven, US based compound and product producer which are in-line with some of other major pharmaceutical companies such as GILD, IDIX as  well as ENTA. The focus thus far for ACHN has been the development and discover of commercial grade medical solutions for several types of diseases which are considered infectious.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) has been working for a long time on a range of products which will help patients to fight diseases such as hepatitis C. Under this disease category the company has also been working on controlling the treatment specifically for the Chronic Hepatitis C infection. The antibacterial solution has also been discovered for resistant bacteria infections. The focus for Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN)  has been four drug candidates. These include- HCV – ACH 1625. This is unique for it is a protease inhibitor, while the NS3 inhibitor is expected to treat HCV.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) is also on the Phase I clinical trial is for the ACH-2928, which is the NS5A inhibitor which is expected to treat HCV. The test is for the Phase I clinical trial. Along with this is the ACH-3102, which is a NS5A inhibitor which will treat HCV. It has also commenced investigations for a new drug- IND, and is expected to file as well as begin the Phase I clinical trial for the same.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.